Sugi Predict

Sugi Predict / Compounds / SCHEMBL2945422

SCHEMBL2945422

SCHEMBL2945422

O=C(O)c1ccc(-c2ccc3c(c2)OCO3)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.73
▸ MAPK1 P28482 1/20 0.73
▸ SRD5A2 P31213 1/20 0.70
▸ GABRA1 P14867 2/20 0.58
▸ GABRB2 P47870 2/20 0.58
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ CTDSP1 Q9GZU7 1/20 0.55
▸ NPC1 O15118 3/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ CA12 O43570 1/20 0.54
▸ CA2 P00918 1/20 0.54
▸ CA9 Q16790 1/20 0.54
▸ RAB9A P51151 2/20 0.52
▸ LMNA P02545 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ PAX8 Q06710 1/20 0.52
▸ CTNNB1 P35222 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14886674 0.89 ALDH1A1 (0.58) ALDH1A1MAPK1SRD5A2NPC1RAB9A
SCHEMBL6535581 0.87 ALDH1A1 (0.70) ALDH1A1MAPK1SRD5A2GABRA1GABRB2
Piperonylic Acid SCHEMBL142318 0.85 ALDH1A1 (1.00) ALDH1A1MAPK1SRD5A2MEN1KMT2A
Piperonylic Acid SCHEMBL3946119 0.85 ALDH1A1 (1.00) ALDH1A1MAPK1SRD5A2MEN1KMT2A
Piperonylic Acid SCHEMBL31119409 0.85 ALDH1A1 (1.00) ALDH1A1MAPK1SRD5A2MEN1KMT2A
SCHEMBL5899521 0.84 CHEK2 (0.67) ALDH1A1MAPK1SRD5A2GABRA1GABRB2
Piperonylic Acid SCHEMBL27389002 0.84 ALDH1A1 (0.83) ALDH1A1MAPK1SRD5A2MEN1KMT2A
SCHEMBL31574502 0.84 GABRA1 (0.61) ALDH1A1MAPK1SRD5A2GABRA1GABRB2
SCHEMBL4097987 0.84 GABRA1 (0.61) ALDH1A1MAPK1SRD5A2GABRA1GABRB2
Piperonylic Acid SCHEMBL1184937 0.83 ALDH1A1 (0.96) ALDH1A1MAPK1SRD5A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167447-A1 Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof GENETIC INTELLIGENCE INC (US) 2023-06-01 — — US disclosed
EP-2772484-B1 BICYCLIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC (JP) 2017-06-28 — — EP disclosed
CN-103917524-B Bicyclic heterocycles ASTELLAS PHARMA INC. (JP) 2016-05-04 — — CN disclosed
US-9266840-B2 Bicyclic heterocyclic compound ASTELLAS PHARMA INC. (JP) 2016-02-23 — — US disclosed
US-20140249151-A1 BICYCLIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC. (JP) 2014-09-04 — — US disclosed
EP-2772484-A1 BICYCLIC HETEROCYCLIC COMPOUND Astellas Pharma Inc. (JP) 2014-09-03 — — EP disclosed
CN-103917524-A Bicyclic heterocyclic compound ASTELLAS PHARMA INC 2014-07-09 — — CN disclosed
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 — — US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 — — US disclosed
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 — — US disclosed
US-20060142333-A1 Vanilloid receptor modulators MACDONALD GREGOR J 2006-06-29 — — US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 — — EP disclosed
EP-1480954-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-12-01 — — EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 — — US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 — — US disclosed
WO-2003068749-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2003-08-21 — — WO disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 — — EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 — — US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 — — US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 ALDH1A1 2651/4885MAPK1 2657/4885SRD5A2 2301/4885
US-20140249151-A1 BICYCLIC HETEROCYCLIC COMPOUND HSD11B1, HSD17B11, HSD17B1 ALDH1A1 349/4885MAPK1 1088/4885SRD5A2 28/4885
US-20060142333-A1 Vanilloid receptor modulators TRPV1, NPSR1, TRPV3 ALDH1A1 2107/4885MAPK1 2220/4885SRD5A2 1530/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 ALDH1A1 2460/4885MAPK1 2730/4885SRD5A2 2279/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 ALDH1A1 2651/4885MAPK1 2657/4885SRD5A2 2301/4885
US-20230167447-A1 Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof FNIP1, FN1, TNNC1 ALDH1A1 4324/4885MAPK1 3071/4885SRD5A2 4620/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR ALDH1A1 3404/4885MAPK1 4010/4885SRD5A2 2695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.